tetano
Editor, Senior Moderator
Antivir Ther. 2016 Dec 7. doi: 10.3851/IMP3115. [Epub ahead of print]
[h=1]Activity of Ergoferon against lethal influenza A (H3N2) virus infection in mice.[/h] Skarnovich MA[SUP]1[/SUP], Emelyanova AG[SUP]2[/SUP], Petrova NV[SUP]2[/SUP], Borshcheva AA[SUP]3[/SUP], Gorbunov EA[SUP]3[/SUP], Mazurkov OY[SUP]1[/SUP], Skarnovich MO[SUP]1[/SUP], Tarasov SA[SUP]3[/SUP], Shishkina LN[SUP]1[/SUP], Epstein OI[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] The Influenza A virus accounts for serious annual viral upper respiratory tract infections. It is constantly able to modify its antigenic structure, thus evading host defence mechanisms. Moreover, currently available anti-influenza agents have a rather limited application, emphasising the further need for new effective treatments. One of them is Ergoferon, a drug, containing combined polyclonal antibodies - anti-interferon gamma, anti-CD4 receptor, and anti-histamine - in released-active form. The purpose of the study was to assess Ergoferon antiviral efficacy in mice challenged with the A/Aichi/2/68 (H3N2) influenza virus.
[h=4]METHODS:[/h] The virus was inoculated intranasally at a 90% lethal dose. Ergoferon was administered at 0.4 ml/day per os in a preventive and therapeutic regimen - daily for 5 days prior to and for 16 days after the challenge. The reference product, Tamiflu (Oseltamivir), was used as a positive control treatment - at 20 mg/kg/day for 5 days after the challenge. Mice in the negative control group received distilled water which had been utilised for test sample preparation; untreated control animals received no treatment. Antiviral efficacy was assessed by an increase in survival rate, average life expectancy, and virus titer reduction in the challenged mice's lungs.
[h=4]RESULTS:[/h] Survival rate and average life expectancy values were increased significantly in groups treated with Ergoferon and Tamiflu, as compared to controls. Lung virus titers were reduced in these groups as observed on days 2 and 4 post inoculation.
[h=4]CONCLUSIONS:[/h] Ergoferon demonstrated antiviral activity by reducing the severity and duration of the major signs of induced influenza infection.
PMID: 27924780 DOI: 10.3851/IMP3115
[PubMed - as supplied by publisher]
[h=1]Activity of Ergoferon against lethal influenza A (H3N2) virus infection in mice.[/h] Skarnovich MA[SUP]1[/SUP], Emelyanova AG[SUP]2[/SUP], Petrova NV[SUP]2[/SUP], Borshcheva AA[SUP]3[/SUP], Gorbunov EA[SUP]3[/SUP], Mazurkov OY[SUP]1[/SUP], Skarnovich MO[SUP]1[/SUP], Tarasov SA[SUP]3[/SUP], Shishkina LN[SUP]1[/SUP], Epstein OI[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] The Influenza A virus accounts for serious annual viral upper respiratory tract infections. It is constantly able to modify its antigenic structure, thus evading host defence mechanisms. Moreover, currently available anti-influenza agents have a rather limited application, emphasising the further need for new effective treatments. One of them is Ergoferon, a drug, containing combined polyclonal antibodies - anti-interferon gamma, anti-CD4 receptor, and anti-histamine - in released-active form. The purpose of the study was to assess Ergoferon antiviral efficacy in mice challenged with the A/Aichi/2/68 (H3N2) influenza virus.
[h=4]METHODS:[/h] The virus was inoculated intranasally at a 90% lethal dose. Ergoferon was administered at 0.4 ml/day per os in a preventive and therapeutic regimen - daily for 5 days prior to and for 16 days after the challenge. The reference product, Tamiflu (Oseltamivir), was used as a positive control treatment - at 20 mg/kg/day for 5 days after the challenge. Mice in the negative control group received distilled water which had been utilised for test sample preparation; untreated control animals received no treatment. Antiviral efficacy was assessed by an increase in survival rate, average life expectancy, and virus titer reduction in the challenged mice's lungs.
[h=4]RESULTS:[/h] Survival rate and average life expectancy values were increased significantly in groups treated with Ergoferon and Tamiflu, as compared to controls. Lung virus titers were reduced in these groups as observed on days 2 and 4 post inoculation.
[h=4]CONCLUSIONS:[/h] Ergoferon demonstrated antiviral activity by reducing the severity and duration of the major signs of induced influenza infection.
PMID: 27924780 DOI: 10.3851/IMP3115
[PubMed - as supplied by publisher]